4TEEN4 Pharma Secures €55M for Cardiogenic Shock Drug
November 18, 2025, 9:34 pm
4TEEN4 Pharmaceuticals got €55M. The money will boost their drug for cardiogenic shock. Procizumab is the drug. It targets a key cause of this deadly condition. Trials are expanding in Europe. US trials are planned. This investment fuels hope for a breakthrough.
Berlin-based 4TEEN4 Pharmaceuticals has secured a significant €55 million in an extension of its Series C financing round. The funds are earmarked to accelerate the clinical development of procizumab. Procizumab is a novel monoclonal antibody. It targets cardiogenic shock. This condition carries a high mortality rate.
Cardiogenic shock results from heart failure. It leads to organ dysfunction. Mortality rates exceed 50%. Current treatments offer only supportive care. Procizumab offers a new approach. It neutralizes circulating dipeptidyl peptidase 3 (cDPP3). cDPP3 is a key driver of cardiovascular collapse. By targeting cDPP3, procizumab aims to restore stability.
The Phase 2a PROCARD 2a trial is ongoing. It assesses procizumab's safety. Tolerability is also being assessed. Pharmacokinetics and pharmacodynamics are assessed. The trial involves patients with cardiogenic shock. Patients have elevated cDPP3 levels. 4TEEN4 dosed its first patient in July 2025. Initial data is expected in early 2026.
The new funding supports trial expansion. More sites across Europe will be added. Plans are underway for US trials. This broadens patient access to procizumab. It strengthens operational readiness. A pivotal late-stage trial is planned.
Procizumab has shown promise. It restores cardiovascular stability. It inhibits CDPP3 activity. This rebalances the renin-angiotensin-aldosterone system. This system is disrupted in shock. Preclinical data shows improvements. Cardiovascular parameters improved. Organ dysfunction reversed. Survival rates increased. The safety profile is favorable. This was demonstrated in a Phase 1 study. Healthy volunteers were involved.
Existing investors participated in the round. New institutional funds joined. Family offices invested. Private investors also participated. This shows strong confidence. They are confident in 4TEEN4's mission. They see the potential of procizumab.
4TEEN4 aims to transform shock treatment. Current treatments are only supportive. Procizumab addresses the biological cause. The goal is to reduce mortality. Critically ill patients will benefit.
Cardiogenic shock is a major unmet need. No approved therapies exist. Existing treatments don't address the underlying mechanisms. Procizumab could be a breakthrough.
4TEEN4 is focused on key milestones. Interim safety data is expected. Pharmacokinetic analysis is planned. Pharmacodynamic analysis is expected in early 2026. Subsequent PROCARD 2a readouts will follow. This capital de-risks the lead candidate. It accelerates progress towards transformative data. This benefits patients in urgent need.
Procizumab has the potential to transform care. It could significantly improve outcomes. It targets a critical unmet need. The €55 million investment is a major step. It brings 4TEEN4 closer to delivering a life-saving therapy. The company hopes to combat life-threatening shock.
4TEEN4 Pharma Expands Series C, Aims to Conquer Cardiogenic Shock with Procizumab
Berlin-based 4TEEN4 Pharmaceuticals has secured a significant €55 million in an extension of its Series C financing round. The funds are earmarked to accelerate the clinical development of procizumab. Procizumab is a novel monoclonal antibody. It targets cardiogenic shock. This condition carries a high mortality rate.
Targeting the Root Cause of Shock
Cardiogenic shock results from heart failure. It leads to organ dysfunction. Mortality rates exceed 50%. Current treatments offer only supportive care. Procizumab offers a new approach. It neutralizes circulating dipeptidyl peptidase 3 (cDPP3). cDPP3 is a key driver of cardiovascular collapse. By targeting cDPP3, procizumab aims to restore stability.
Clinical Trials Underway
The Phase 2a PROCARD 2a trial is ongoing. It assesses procizumab's safety. Tolerability is also being assessed. Pharmacokinetics and pharmacodynamics are assessed. The trial involves patients with cardiogenic shock. Patients have elevated cDPP3 levels. 4TEEN4 dosed its first patient in July 2025. Initial data is expected in early 2026.
Expansion Plans
The new funding supports trial expansion. More sites across Europe will be added. Plans are underway for US trials. This broadens patient access to procizumab. It strengthens operational readiness. A pivotal late-stage trial is planned.
Promising Preclinical Data
Procizumab has shown promise. It restores cardiovascular stability. It inhibits CDPP3 activity. This rebalances the renin-angiotensin-aldosterone system. This system is disrupted in shock. Preclinical data shows improvements. Cardiovascular parameters improved. Organ dysfunction reversed. Survival rates increased. The safety profile is favorable. This was demonstrated in a Phase 1 study. Healthy volunteers were involved.
Investor Confidence
Existing investors participated in the round. New institutional funds joined. Family offices invested. Private investors also participated. This shows strong confidence. They are confident in 4TEEN4's mission. They see the potential of procizumab.
Aims Beyond Supportive Care
4TEEN4 aims to transform shock treatment. Current treatments are only supportive. Procizumab addresses the biological cause. The goal is to reduce mortality. Critically ill patients will benefit.
The Need is Urgent
Cardiogenic shock is a major unmet need. No approved therapies exist. Existing treatments don't address the underlying mechanisms. Procizumab could be a breakthrough.
Looking Ahead
4TEEN4 is focused on key milestones. Interim safety data is expected. Pharmacokinetic analysis is planned. Pharmacodynamic analysis is expected in early 2026. Subsequent PROCARD 2a readouts will follow. This capital de-risks the lead candidate. It accelerates progress towards transformative data. This benefits patients in urgent need.
A Potential Game-Changer
Procizumab has the potential to transform care. It could significantly improve outcomes. It targets a critical unmet need. The €55 million investment is a major step. It brings 4TEEN4 closer to delivering a life-saving therapy. The company hopes to combat life-threatening shock.